Christopher TenHoor

This inventor holds 14 USPTO granted patents and 9 published patent applications and 10 EPO patents. Top assignees: Dyax Corporation, Takeda Pharmaceutical Company Limited, Syntonix Pharmaceuticals, Inc.. Active years: 2012-2025.

USPTO Granted Patents = 14 (Patent Applications = 9)

% Patents Active = 100.0

EPO Patents = 10 (Patent Applications = 10)

Average Co-Inventor Count = 4.8

ph-index = 5

Forward Citations = 91(Granted Patents)

Company Filing History:

Takeda Pharmaceutical Company Limited

patents

2 out of 14

Syntonix Pharmaceuticals, Inc.

patents

4. 1 out of 2

Biogen Hemophilia Inc.

patents

where one patent can have more than one assignee

Years Active: 2012-2025

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12454575 - Nucleic acids encoding FcRn-binding antibodies, pharmaceutical compositions thereof and methods of use thereof to make antibodies (2025-10-28),

2. 12442824 - Assays for determining plasma kallikrein system biomarkers (2025-10-14),

3. 12384854 - Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema (2025-08-12),

4. 11739152 - Antibodies which bind Fc receptors (FcRn) (2023-08-29),

5. 11372002 - Assays for determining plasma kallikrein system biomarkers (2022-06-28),

6. 11156612 - Methods of determining levels of cleaved and/or intact kininogen (2021-10-26),

7. 11084884 - Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema (2021-08-10),

8. 11014988 - Nucleic acids encoding anti-neonatal Fc receptor (FcRn) antibodies (2021-05-25),

9. 10479834 - Fc receptor antibodies and methods of use thereof (2019-11-19),

10. 9862768 - Methods of producing antibodies to neonatal Fc receptor (FcRn) (2018-01-09),

11. 9359438 - Human neonatal Fc receptor antibodies and methods of use thereof (2016-06-07),

12. 9260520 - Antibodies to FeRn and uses thereof (2016-02-16),

13. 8815246 - Fc receptor binding proteins (2014-08-26),

14. 8273351 - Fc receptor binding proteins (2012-09-25),

Title: The Innovative Contributions of Christopher TenHoor

Introduction

Christopher TenHoor, an accomplished inventor based in Hopkinton, Massachusetts, holds an impressive portfolio of 12 patents. His work primarily focuses on the development of therapeutic proteins, particularly those targeting critical health conditions. TenHoor’s inventions play a significant role in advancing medical treatments that can greatly impact patient lives.

Latest Patents

Among his latest patents are groundbreaking innovations in the field of protein therapeutics. One notable patent discusses plasma kallikrein binding proteins and their applications in treating hereditary angioedema. This patent provides insights into antibodies that specifically target active plasma kallikrein, offering new hope for individuals suffering from this severe condition. Another significant patent focuses on antibodies that bind to Fc receptors (FcRn), revealing methods for utilizing these antibodies in various therapeutic applications.

Career Highlights

Christopher TenHoor has significantly contributed to the pharmaceutical industry through his tenures at notable companies like Dyax Corporation and Takeda Pharmaceutical Company Limited. His expertise and innovations have helped pave the way for advanced treatment options in rare and difficult-to-treat medical conditions.

Collaborations

Throughout his career, TenHoor has collaborated with esteemed professionals in the field, including Daniel J. Sexton and Malini Viswanathan. These partnerships have enabled the exchange of ideas and expertise, further enhancing the development of innovative therapeutic solutions.

Conclusion

In conclusion, Christopher TenHoor's contributions to the field of medical technology through his patents and collaborations exemplify the spirit of innovation. His work not only demonstrates his inventive prowess but also showcases the important intersection of science and healthcare, ultimately aiming to improve patient outcomes and advance medical treatments.